{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T23:49:13Z","timestamp":1781912953486,"version":"3.54.5"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T00:00:00Z","timestamp":1260921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>The oncogenic human herpes virus, the Epstein\u2013Barr virus (EBV), expresses EBNA1 in almost all forms of viral latency. EBNA1 plays a major role in the maintenance of the viral genome and in the transactivation of viral transforming genes, including EBNA2 and latent membrane protein (LMP\u20101). However, it is unknown whether inhibition of EBNA1 from the onset of EBV infection disrupts the establishment of EBV\u2019s latency and transactivation of the viral oncogenes. To address this, we measured EBV infection kinetics in the B cell lines BALL\u20101 and BJAB, which stably express a dominant\u2010negative EBNA1 (dnE1) fused to green fluorescent protein (GFP). The EBV genome was surprisingly unstable 1\u2003week post\u2010infection: the average loss rate of EBV DNA from GFP\u2010 and GFP\u2010dnE1\u2010expressing cells was 53.4% and 41.0% per cell generation, respectively, which was substantially higher than that of an \u2018established\u2019<jats:italic>oriP<\/jats:italic> replicon (2\u20134%). GFP\u2010dnE1 did not accelerate loss of the EBV genome, suggesting that EBNA1\u2010dependent licensing of the EBV genome occurs infrequently during the acute phase of EBV infection. In the subacute phase, establishment of EBV latency was completely blocked in GFP\u2010dnE1\u2010expressing cells. In contrast, C\/W promoter\u2010driven transcription was strongly restricted in GFP\u2010dnE1\u2010expressing cells at 2\u2003days post\u2010infection. These data suggest that inhibition of EBNA1 from the onset of EBV infection is effective in blocking the positive feedback loop in the transactivation of viral transforming genes, and in eradicating the EBV genome during the subacute phase. Our results suggest that gene transduction of GFP\u2010dnE1 could be a promising therapeutic and prophylactic approach toward EBV\u2010associated malignancies.<\/jats:p><jats:p>(<jats:italic>Cancer Sci<\/jats:italic> 2010; 101: 876\u2013881)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01474.x","type":"journal-article","created":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T20:41:18Z","timestamp":1260996078000},"page":"876-881","source":"Crossref","is-referenced-by-count":4,"title":["Dominant\u2010negative derivative of EBNA1 represses EBNA1\u2010mediated transforming gene expression during the acute phase of Epstein\u2013Barr virus infection independent of rapid loss of viral genome"],"prefix":"10.1111","volume":"101","author":[{"given":"Yumi","family":"Kariya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Hamatake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Urano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Komano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,16]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0670-3"},{"key":"e_1_2_7_3_2","first-page":"2655","volume-title":"Fields Virology","author":"Rickinson AB","year":"2007"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210240"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2006.01650.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.8.2339"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180315"},{"key":"e_1_2_7_8_2","first-page":"2603","volume-title":"Fields Virology","author":"Kieff E","year":"2007"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.plasmid.2007.01.003"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20324"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.69.2.1280-1283.1995"},{"key":"e_1_2_7_12_2","first-page":"85","article-title":"Plasmid origin of replication of Epstein\u2013Barr virus, oriP, does not limit replication in cis","volume":"5","author":"Sugden B","year":"1988","journal-title":"Mol Biol Med"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.13.4149-4161.2001"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.168.6.2059"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605985103"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2336099100"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.12.017"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.71.3.1766-1775.1997"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e04-04-0279"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.49.33073"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.66.1.489-495.1992"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2008.10.047"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32801424a5"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.13.7004-7015.2004"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.5.3349"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90797-6"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/590502"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01474.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01474.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:03:47Z","timestamp":1730304227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01474.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,16]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01474.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01474.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,16]]}}}